Seeking Alpha

surferdan

surferdan
Send Message
View as an RSS Feed
View surferdan's Comments BY TICKER:
Latest  |  Highest rated
  • Questcor - The Deal Of A Lifetime [View article]
    QTR, you certainly make up in quantity for the lack of quality in your many, many, many posts.
    sd
    Mar 3 09:22 AM | 5 Likes Like |Link to Comment
  • Questcor falls; Citron claims Acthar at risk of being pulled [View news story]
    Does Seeking Alpha have no shame?
    Feb 27 10:42 AM | 13 Likes Like |Link to Comment
  • The Idiot's Guide To Why Questcor Is Suspicious [View article]
    @Dr Fred, I certainly have reservations about you calling yourself a doctor to start with.
    "No MD I know is willing to try some other drug when Acthar gel works so well" Now, if you actually were a doctor, you would already know that Acthar Gel is the Rx of LAST resort and therefore all doctors have already tried other treatments, making your statement moot and borderline lie. After reading your statement, I prefer to move on to more educated reply's.
    Dec 20 03:54 PM | 3 Likes Like |Link to Comment
  • Questcor -4.6% AH on Retrophin synthetic ACTH development candidate news [View news story]
    dr, and where does this company get the bucks to fund these trials?
    Dec 17 05:55 PM | 2 Likes Like |Link to Comment
  • The Curious Case Of Questcor Pharmaceuticals [View article]
    "Article reveals nothing new. Commenters don't either. "
    After reading your reply, I must say it reveals nothing new either and sounds very much like Andrew Left's articles which reveal nothing except half truths, out right lies, and innuendos.

    If you don't think the 10% figure is correct, supply one that you know is correct or just don't mention that you know nothing and like to write crap with nothing to back it up.
    QCOR supplies people with medication that is very helpful for them, and for that they make piles of money and that is why the stock is moving in the right direction in spite of trash articles written by your lord, Andrew Left, felon.
    Dec 16 08:27 PM | 3 Likes Like |Link to Comment
  • Affymax: Putting The Pieces Together [View article]
    Very well written article. Great job! I follow you on the YMB,s and appreciate all the research you provide for us.

    sd
    Aug 24 10:14 AM | 5 Likes Like |Link to Comment
  • Ebix: Better Timely Than Good [View article]
    I bet your 3rd grade English teacher would be very proud of you.
    Jun 24 01:21 PM | 4 Likes Like |Link to Comment
  • Ebix Worth No More Than $8, Likely Headed To $0 [View article]
    It certainly wasn't your exquisite writing! LOL
    Were your other 182 posts just bashing someone else?

    sd
    Jun 22 11:21 AM | Likes Like |Link to Comment
  • Ebix Worth No More Than $8, Likely Headed To $0 [View article]
    It does not surprise me at all that S A would allow a pathetic post like this to make the site just 2 days after removing a post about QCOR that was actually based on facts and had links to back it up. I think this rag has strayed way too far from any resemblance of journalism and has become a shill of the shorts. Good bye seekingalpha, have a good life
    sd
    Jun 21 10:20 AM | 13 Likes Like |Link to Comment
  • Was The Aetna News Overblown? Blue Cross Blue Shield Supports Questcor's H.P. Acthar Gel [View article]
    Yes, kind of like GM and Ford. They only make one thing, vehicles.
    Jun 1 12:18 PM | 4 Likes Like |Link to Comment
  • Questcor's (QCOR -7.3%) early drubbing was apparently due to a mistaken headline stating that a synthetic version of Acthar had been approved by the FDA, rather than the Orphan Drug Designation it had actually been given, according to a Seeking Alpha contributor. The errant headline has since been pulled and refiled to reflect the correction, but the hangover in the shares continues in mid-day trading nontheless. [View news story]
    I doubt that there was any "mistaken headline". This was just one more in a line of false reporting and should be investigated to the fullest!
    Nov 2 04:06 PM | Likes Like |Link to Comment
  • Questcor III: After The Earnings [View article]
    Another in a line of very well researched and written article on the subject of QCOR. If only Citron could be one tenth as balenced in their articles we would still be above $50.00 a share.
    Oct 30 10:17 PM | 1 Like Like |Link to Comment
  • Insurers are taking an even more cautious stance on Questcor's (QCOR -4.1%) Acthar, according to a Citron Research report. The short seller is now claiming that Humana (HUM -1.5%) has issued a new Commercial Preauthorization document containing a new, specifically asterisked preauthorization for reimbursement for Acthar, which it contends is part of a pattern of insurers taking a more restrictive stance on authorization policy with regard to the drug's reimbursement. [View news story]
    Association your company with a rag like Citron speaks volumes about Seeking Alpha. Try doing some research prior to parroting a known short rag like Citron. Yes, journalism is dead!
    surferdan
    Oct 20 03:24 AM | Likes Like |Link to Comment
  • Amazon (AMZN) roundup: 1) Bloomberg reports Amazon is in talks to buy Brazilian bookseller Saraiva. Saraiva, which currently has a market cap of $356M, is both a publisher and retailer of books (online and via physical stores). The report appears to be pressuring MercadoLibre (MELI -3.5%), which has already fallen on worries Amazon will enter Brazil. 2) The WSJ observes Amazon is struggling to make its publishing efforts a success in the face of boycotts from many booksellers. (earlier: I, II[View news story]
    Isn't it ironic that MELI falls over $3.00 a share prior to any announcement about the AMZN purchase? And the world wonders why the retail investor will not enter the stock market. LOL
    surferdan
    Oct 18 02:06 PM | Likes Like |Link to Comment
  • What Happens To Questcor Now? [View article]
    Yes, but Questor states that their drug should only be used when the cheaper drugs are ineffective. If your headache continued for days and days after taking that Excederine, you might be interested in the more expensive product.
    Sep 26 09:17 AM | Likes Like |Link to Comment
COMMENTS STATS
16 Comments
53 Likes